[Clinical significance of blood glucose levels in the pathogenesis of (atherosclerotic) macroangiopathy]
- PMID: 15156691
[Clinical significance of blood glucose levels in the pathogenesis of (atherosclerotic) macroangiopathy]
Abstract
Numerous authors suggested postprandial blood glucose elevation as a significant contributor in development of macroangiopathy. Epidemiological studies and animal experiments delivered supportive data about causal relationship between postprandial hyperglycaemia and macroangiopathy in type 2 diabetes. Interestingly there is no chronological correlation between presence of hyperglycaemia and development of macroangiopathy neither in type 2, nor in type 1 diabetics. Strict metabolic control does not result in slowing progression of macroangiopathy (glucose paradox). Premature macroangiopathy documented in the prediabetes phase of type 2 diabetes is strongly related to presence of insulin resistance, hyperinsulinaemia, high blood pressure, and dyslipidaemia; development of atherosclerosis in advanced stage of type 1 diabetes is also rather associated with presence of high blood pressure and dyslipidaemia but not that of hyperglycaemia. With regard to role of postprandial hyperglycaemia it should be emphasized, that not the postprandial blood glucose elevation per se, but rather the postprandial complex metabolic cluster (hyperinsulinaemia, hypertrygliceriadaemia, etc) is supposed to be related with development of macroangiopathy in patients with metabolic syndrome and type 2 diabetes.
Similar articles
-
[Postprandial hyperglycemia. Postprandial blood glucose fluctuations, cardiovascular disease and late diabetic complications].Ugeskr Laeger. 2003 Aug 11;165(33):3149-53. Ugeskr Laeger. 2003. PMID: 12968409 Review. Danish.
-
Clinical significance of post-prandial blood glucose excursions in type 1 and type 2 diabetes mellitus.Int J Clin Pract Suppl. 2000 Sep;(112):9-12. Int J Clin Pract Suppl. 2000. PMID: 11064945 Review. No abstract available.
-
[The role of postprandial hyperglycemia in the development of cardiovascular diseases in type 2 diabetes mellitus].Klin Med (Mosk). 2009;87(11):17-24. Klin Med (Mosk). 2009. PMID: 20143560 Review. Russian.
-
Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.Med Hypotheses. 2005;65(1):152-4. doi: 10.1016/j.mehy.2004.12.008. Epub 2005 Jan 28. Med Hypotheses. 2005. PMID: 15893133
-
Postprandial lipemia: an under-recognized atherogenic factor in patients with diabetes mellitus.Int J Cardiol. 2008 May 7;126(1):3-12. doi: 10.1016/j.ijcard.2007.04.172. Epub 2007 Aug 8. Int J Cardiol. 2008. PMID: 17689745 Review.